BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38071325)

  • 1. ARID1A loss activates MAPK signaling via DUSP4 downregulation.
    Mandal J; Yu ZC; Shih IM; Wang TL
    J Biomed Sci; 2023 Dec; 30(1):94. PubMed ID: 38071325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming.
    Suryo Rahmanto Y; Shen W; Shi X; Chen X; Yu Y; Yu ZC; Miyamoto T; Lee MH; Singh V; Asaka R; Shimberg G; Vitolo MI; Martin SS; Wirtz D; Drapkin R; Xuan J; Wang TL; Shih IM
    Nat Commun; 2020 Jun; 11(1):2717. PubMed ID: 32483112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of dual-specificity phosphatase 4 enhances cell proliferation and invasiveness in colorectal carcinomas.
    Ichimanda M; Hijiya N; Tsukamoto Y; Uchida T; Nakada C; Akagi T; Etoh T; Iha H; Inomata M; Takekawa M; Moriyama M
    Cancer Sci; 2018 Jan; 109(1):250-258. PubMed ID: 29150975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion.
    Mazumdar A; Poage GM; Shepherd J; Tsimelzon A; Hartman ZC; Den Hollander P; Hill J; Zhang Y; Chang J; Hilsenbeck SG; Fuqua S; Kent Osborne C; Mills GB; Brown PH
    Breast Cancer Res Treat; 2016 Aug; 158(3):441-54. PubMed ID: 27393618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DUSP4 is involved in the enhanced proliferation and survival of DUSP4-overexpressing cancer cells.
    Ratsada P; Hijiya N; Hidano S; Tsukamoto Y; Nakada C; Uchida T; Kobayashi T; Moriyama M
    Biochem Biophys Res Commun; 2020 Jul; 528(3):586-593. PubMed ID: 32505357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
    Wiegand KC; Hennessy BT; Leung S; Wang Y; Ju Z; McGahren M; Kalloger SE; Finlayson S; Stemke-Hale K; Lu Y; Zhang F; Anglesio MS; Gilks B; Mills GB; Huntsman DG; Carey MS
    BMC Cancer; 2014 Feb; 14():120. PubMed ID: 24559118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation.
    Gröschl B; Bettstetter M; Giedl C; Woenckhaus M; Edmonston T; Hofstädter F; Dietmaier W
    Int J Cancer; 2013 Apr; 132(7):1537-46. PubMed ID: 22965873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A.
    Wu CH; Mao TL; Vang R; Ayhan A; Wang TL; Kurman RJ; Shih IeM
    Int J Gynecol Pathol; 2012 Jul; 31(4):297-303. PubMed ID: 22653341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency.
    Jung HH; Lee SH; Kim JY; Ahn JS; Park YH; Im YH
    Sci Rep; 2016 Sep; 6():33035. PubMed ID: 27604655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ARID1A mutations in endometriosis-associated ovarian carcinomas.
    Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
    N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma.
    Guan B; Mao TL; Panuganti PK; Kuhn E; Kurman RJ; Maeda D; Chen E; Jeng YM; Wang TL; Shih IeM
    Am J Surg Pathol; 2011 May; 35(5):625-32. PubMed ID: 21412130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma.
    Ayhan A; Mao TL; Seckin T; Wu CH; Guan B; Ogawa H; Futagami M; Mizukami H; Yokoyama Y; Kurman RJ; Shih IeM
    Int J Gynecol Cancer; 2012 Oct; 22(8):1310-5. PubMed ID: 22976498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Dusp4 and p53 loss with Dbf4 amplification drives tumorigenesis via cell cycle restriction and replication stress escape in breast cancer.
    Hanna A; Nixon MJ; Estrada MV; Sanchez V; Sheng Q; Opalenik SR; Toren AL; Bauer J; Owens P; Mason FM; Cook RS; Sanders ME; Arteaga CL; Balko JM
    Breast Cancer Res; 2022 Jul; 24(1):51. PubMed ID: 35850776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DUSP4 appears to be a highly localized endogenous inhibitor of epileptic signaling in human neocortex.
    Kirchner A; Bagla S; Dachet F; Loeb JA
    Neurobiol Dis; 2020 Nov; 145():105073. PubMed ID: 32890776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ARID1A Regulates Progesterone Receptor Expression in Early Endometrial Endometrioid Carcinoma Pathogenesis.
    Asaka S; Liu Y; Yu ZC; Rahmanto YS; Ono M; Asaka R; Miyamoto T; Yen TT; Ayhan A; Wang TL; Shih IM
    Mod Pathol; 2023 Feb; 36(2):100045. PubMed ID: 36853791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level.
    Goldman AR; Bitler BG; Schug Z; Conejo-Garcia JR; Zhang R; Speicher DW
    Mol Cell Proteomics; 2016 Nov; 15(11):3348-3360. PubMed ID: 27654507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma.
    Mao TL; Ardighieri L; Ayhan A; Kuo KT; Wu CH; Wang TL; Shih IeM
    Am J Surg Pathol; 2013 Sep; 37(9):1342-8. PubMed ID: 24076775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.
    Balko JM; Cook RS; Vaught DB; Kuba MG; Miller TW; Bhola NE; Sanders ME; Granja-Ingram NM; Smith JJ; Meszoely IM; Salter J; Dowsett M; Stemke-Hale K; González-Angulo AM; Mills GB; Pinto JA; Gómez HL; Arteaga CL
    Nat Med; 2012 Jul; 18(7):1052-9. PubMed ID: 22683778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer.
    Balko JM; Schwarz LJ; Bhola NE; Kurupi R; Owens P; Miller TW; Gómez H; Cook RS; Arteaga CL
    Cancer Res; 2013 Oct; 73(20):6346-58. PubMed ID: 23966295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptional regulation of human DUSP4 gene by cancer-related transcription factors.
    Varela T; Conceição N; Laizé V; Cancela ML
    J Cell Biochem; 2021 Oct; 122(10):1556-1566. PubMed ID: 34254709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.